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Background: Across Europe, illicit drug-related mortality has not declined despite ever increasing prevention
measures. The cause of these deaths has traditionally been associated with overdose. Previous findings have
revealed the appearance of non-lethal opioid concentrations, leading us to investigate a further cause of death.
The symptoms of heroin intoxication with asphyxia and/or cardiovascular involvement resemble anaphylaxis, and
therefore it has been speculated that such deaths might be caused by an allergic reaction. The study´s aims were
to investigate levels of allergic mediators in long-term injecting drug users (IDU) compared to healthy controls and
to determine if oral opioid substitution therapy (OST) resulted in similar allergic symptoms to those reported by IDU
after intravenous (IV) heroin use.
Methods: We quantified the concentrations of histamine, diamine oxidase (DAO), tryptase and lipoprotein-associated
phospholipase A2 (LpPLA2) at baseline and 1 h after administration of Substitol®retard (482 ± 220 mg) in 56 patients at
a withdrawal centre (Austria) and compared them with healthy controls (n = 103). Questionnaires and face-to-face
interviews were used to assess allergic symptoms and side effects in IDU. Descriptive statistical analyses of quantitative
data were performed by using SPSS.
Results: Baseline histamine, tryptase and LpPLA2 were significantly elevated in IDU compared to the healthy control
group, while DAO decreased. Blood levels showed no significant change after oral substitution uptake. Self-reported
allergic symptoms and side effects after IV heroin use were reported in 55 cases (98.2%), minimal symptoms were
documented after OST (12.5%, 7/56).
Conclusions: This study revealed that baseline histamine concentrations were elevated in chronic IDU, although only
relatively small changes in tryptase plasma levels occurred. After IV heroin application the reported allergic symptoms
were mostly mild and did not lead to clinically relevant side effects. The substitution substance was clearly better
tolerated than IV administered heroin. Elevated levels of allergic mediators such as histamine in IDUs may place them
at greater risk of severe or fatal anaphylaxis when exposed to heroin; however, this requires further investigation.
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Drug-related mortality is often marked by a lack of dem-
onstrable cause of death. Death due to overdose may be
misleading in many cases [1-3]. Several studies have
shown a wide range of morphine concentrations, usually
non-lethal, in post-mortem samples with coincidental
poly drug-use [1,4-6], leading us to investigate a further* Correspondence: ute.maurer@fhwn.ac.at
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unless otherwise stated.cause of death. The symptoms of heroin intoxication
with asphyxia and/or cardiovascular involvement resem-
ble anaphylaxis, and therefore it has been speculated
that such deaths might be caused by an allergic reaction.
Anaphylaxis is a severe, potentially life-threatening aller-
gic reaction affecting multiple organ systems - including
the skin, respiratory tract, gastrointestinal tract and cen-
tral nervous system [7-10]. Common triggers of anaphyl-
axis include certain foods, insect venom and some
medications [10,11]. The essential common factor in ana-
phylaxis, whether by immunological or non- immunologicalLtd. This is an Open Access article distributed under the terms of the Creative
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basophils, with the release of preformed vasoactive media-
tors (such as histamine, mast cell tryptase [MCT] and
chymase), newly synthesized cytokines as well as lipid-
derived mediators [12-16]. These mediators act on target
cells and can induce vasodilation, increased permeability,
hypotension, bronchospasm and as a result, shock. The
symptomatology is variable; there is no obligatory involve-
ment of all organ systems [17,18]. Cutaneous manifesta-
tions (such as pruritus, flushing, urticaria and angioedema)
are by far the most common. But reactions can progress
within minutes to respiratory and/or cardiovascular arrest
with lethal ending.
The diagnosis of anaphylaxis is based primarily on the
clinical picture and history which can be corroborated by
serologic laboratory tests. Currently, there is no in vitro
test for diagnosing anaphylaxis but the serial measure-
ment of immune mediators, such as histamine, MCT as
well as other products of mastocytes or basophils, may be
useful for confirming diagnosis and potentially identifying
risk [19]. Diagnostic criteria for anaphylaxis were pub-
lished by a multidisciplinary group of experts [18] who
agreed on the lack of information about reliable bio-
markers to confirm the clinical impression. Sometimes it
is not feasible to obtain samples within the optimum time
frame [20]. Moreover, even with early collection of sam-
ples, histamine and tryptase may be within normal levels
[20]. Therefore they are described as nonspecific markers
for anaphylaxis which can be increased in other disease
as well [21].
Many opioids are known to stimulate mast cell and
basophil degranulation non-specifically [22,23]. There
are differences in their capacity to cause histamine re-
lease along with other mediators as well in variable
opioid-dependent effects [24].
In the present study, we investigated allergic symp-
toms and side effects in IDU after IV heroin injection
(self-reported) and after opioid substitution treatment
(OST) (observed) within 180 minutes. To determine if
long-term IV heroin use result in altered biomarker levels,
we analyzed allergic mediators in opioid dependent per-




The objectives were addressed by performing quantita-
tive laboratory analysis (immunoassays) and qualitative
data analysis (questionnaires, face-to-face interviews).
Blood samples were obtained from opioid dependent
persons at a withdrawal centre at Amstetten/Mauer
(Austria) who had been undergoing an OST program for
2 weeks. Samples from IDU were taken prior (baseline)
and 1 hour after substitution treatment. The first bloodsampling was conducted 10 minutes before morning ad-
ministration. Subsequent sampling proceeded 1 hour
after oral intake of substitution substance. Blood analysis
served in the determination of baseline allergic bio-
markers, such as histamine, diamine oxidase (DAO),
tryptase and lipoprotein associated phospholipase A2
(LpPLA2). Serum and plasma samples were collected
into plain and EDTA vacutainers, using VACUETTE®
products manufactured by Greiner Bio-One. The tubes
were transported in dry ice and centrifuged within 30 mi-
nutes after sampling. After centrifugation at 3000U/min
for 10 minutes, samples were immediately stored at -20°C
until analysis. Laboratory analyses were performed at the
Floridsdorfer Allergy Centre (FAZ), Vienna (Austria).
Supplementary, the clinical picture of long-term IDU
before and after substitution was documented. Therefore
face-to-face interviews and questionnaire procedures were
used. A structured datasheet was used to record the fol-
lowing factors: demographics, characteristics of allergen/
trigger exposure (kind of opioid, daily dosage, mean dur-
ation of regular abuse, etc.), pre-existent allergic condi-
tions and/or mastocytosis as well as self-reported allergic
reactions and side-effects shown during former IV drug
consumption. After substitution, a structured datasheet
was filled in to record treatments, side effects and individ-
ual reaction features after 15, 30, 60, and 180 minutes.
Study population
All participants gave their written informed consent. Ap-
proval was also obtained from relevant federal author-
ities and the ethics committee.
At the withdrawal centre in Amstetten/Mauer, 78 drug
addicts (58 male/ 20 female) were tested from a patient
population. The key inclusion criteria for OST were a
main diagnosis of opiate dependence according to ICD-
10 [25] as well as suitable venous conditions for blood
sampling. Patients’ age, sex, or ethnic background were
not considered as recruitment criteria for this study. The
presence of underlying allergic disease was reported in
22 of 78 cases, such as medication (n = 11), grass pollen
(n = 8), food (n = 3) and insect sting (n = 2) allergies. Fur-
ther clinical risk factors for anaphylaxis, comprising
comorbidities such as asthma, cardiovascular disease or
mastocytosis, were not recognized. In the final analysis,
56 IDU without underlying allergic disease, were in-
cluded in the study population.
Most subjects had a significant history of regular
opioids abuse, ranging from 2 to 25 years. The mean
duration of regular heroin abuse was 7 ± 5.3 years. All par-
ticipants at the withdrawal centre in Amstetten/Mauer
were treated with Substitol®retard. In Austria, Substitol
found its role in OST programs to treat heroin addiction
as a controlled, slow releasing oral medicine. It is a semi-
synthetic, highly potent and long acting opioid analgesic
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(482 ± 220 mg), depending on type of substance, duration
of intake and daily dosage.
For the comparison group volunteers (n = 103) were
recruited during the same period as the drug addicts be-
tween October 2011 and December 2012. 38 male and
65 female persons were included, ages varied from 18 to




Histamine, a biogenic amine, is the most important in-
flammatory mediator released by degranulation of mast
cells and basophils during an allergic reaction [27,28].
Many opioids are known to be potent histamine relea-
sers [29,30]. Therefore it is of high interest to evaluate
baseline histamine concentrations in chronic IDUs. His-
tamine levels were determined by radioimmunoassay
(Immunotec, France) [31]. In brief, blood was collected
in a chilled tube containing EDTA and immediately
cooled on ice. Samples were centrifuged for 10 minutes
at 900 g/4°C. Acylation buffer and calibrator were then
added and immediately vortexed. Results were obtained
from the standard curve by interpolation. Normal hista-
mine levels in living subjects are <0.3 ng/ml [32].
Diamine oxidase (DAO)
DAO is a major histamine-degrading enzyme which is
found in various tissues, but is primarily active in the in-
testinal mucosa [33]. DAO activity in serum samples of
healthy individuals normally ranged from 10 to 30U/ml.
Lower DAO activity was described as a potential indica-
tor for intestinal mucosa damage in inflammatory and
neoplastic disease [34] as well as in cases of fatal anaphyl-
axis [35]. The activity of DAO was determined by quanti-
tating the reaction product (Sciotec Diagnostics Tulln,
Austria) [36]. Radiolabelled putrescine-dihydrochloride
was used as a substrate. The result Δ1pyrroline, containing
the radiolabel, was extracted selectively from the matrix
by a liquid extraction step. A non-toxic, chlorine-free solv-
ent with high capacity was used for extraction. Finally
scintillation fluid was added to the organic phase con-
taining the radiolabelled Δ1-pyrroline and radioactivity
was determined in a beta-counter. The signal was dir-
ectly proportional to the activity of DAO in the sam-
ple. Results < 11U/ml are judged to be reduced.
Tryptase
Mast cell tryptase (MCT) is a tetrameric neutral serine
protease which is nearly exclusive to mast cells [16,37].
It is more stable, has a longer half-life than histamine
and can be detected from a few minutes up to several
hours after mast cell degranulation [20,38]. Anti-Tryptase,covalently bound to a solid phase reacted with the tryptase
in the serum (Thermo Fisher Scientific, Austria) [39].
After a washing procedure, enzyme labelled antibodies
against tryptase was added to form a complex. After incu-
bation, unbound enzyme anti-tryptase was washed away
and the bound complex incubated with a developer. After
stopping the reaction, the fluorescense of the eluate was
measured. The fluorescence was directly proportional to
the tryptase concentration of the serum. Normal levels
were <11.4 μg/l.
Lipoprotein-associated Phospholipase A2
Lipoprotein-associated phospholipase A2 (LpPLA2), a
Ca2+ independent phospholipase A2, was identified in
human plasma and found to be responsible for hydroly-
sis and inactivation of platelet-activating factor (PAF)
and certain oxidized phospholipids [40]. Although the
role of LpPLA2 as a pro- or anti-atherosclerotic enzyme
is frequently debated, several studies have shown it to be
an independent marker of cardiovascular disease [41,42].
This method (diaDexus, South San Francisco) [43] uti-
lizes monoclonal anti-LpPLA2 antibodies directed against
LpPLA2 for solid phase immobilization on the micro well
plate. Serum samples were added to the plate and after
incubation, second monoclonal anti-LpPLA2 antibody la-
belled with the enzyme horseradish peroxidase, were
added and then incubated with the immobilized antigen.
The added substrate, tetramethylbenzidine, followed the
immunological reaction. The absorbance of the enzymatic
turnover of the substrate was determined by spectropho-
tometry at 450 nm. It was directly proportional to the
present concentration of LpPLA2.
Statistical analysis
Descriptive statistical analyses of quantitative data were
performed by using SPSS, version 20. Comparisons be-
tween groups were made by using the Mann-Withney
Test. Data was expressed as mean ± SD. The level of sig-
nificance was set at 5%.
Results
At baseline, histamine levels were elevated in IDU (0.50 ±
0.30 ng/ml, 95% CI 0.42-0.58 ng/ml) compared to healthy
controls (0.18 ± 0.15 ng/ml, 95% CI 0.15-0.21 ng/ml)
(p < 0.001, Mann-Whitney Test), shown in Figure 1.
We found increased baseline histamine levels (>0.3 ng/ml)
in 45 of 56 IDUs. Baseline DAO concentrations were
decreased in opioid dependent persons (11.8 ± 4.9U/ml,
95% CI 10.43-13.21U/ml), compared to controls (15.7 ±
7.7U/ml, 95% CI 14.19-17.16U/ml) (p < 0.05, Mann-
Whitney Test; see Figure 2). In chronic drug abusers, tryp-
tase values varied between 1 and 20 μg/l (6.0 ± 4.3 μg/l,
95% CI 4.89-7.18 μg/l; Figure 3). In the healthy con-





Histamine in IDUs (0.14-1.58ng/ml) Histamine in CG (0.1-0.9ng/ml)







DAO in IDUs (2.8-23U/ml) DAO in CG (1.8-39U/ml)
Figure 2 Baseline DAO levels (U/ml) measured in injecting drug users (IDUs) and in comparison group (CG), (p < 0.05, Mann-Whitney Test).






Tryptase levels in IDUs (1.0-20.0µg/l) Tryptase levels in CG (1.0-12.55µg/l)
Figure 3 Baseline tryptase levels (μg/l) measured in injecting drug users (IDUs) and in comparison group (CG), (p < 0.001, Mann-Whitney Test).
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Whitney Test). We found high LpPLA2 levels in IDUs
(411.9 ± 125 ng/ml, 95% CI 377.27-446.58 ng/ml) versus
333.3 ± 85.9 ng/ml (95% CI 316.76- 349.80 ng/ml) in





LpPLA2 levels in IDUs (176.1-918.1ng/ml
Figure 4 Baseline LpPLA2 levels (ng/ml) measured in injecting drug
Mann-Whitney Test).Blood levels of all markers showed no significant change
after OST.
After IV heroin, 55 of 56 IDU (98.2%) self-reported al-
lergic symptoms and side effects. The most common
manifestations were cutaneous symptoms which occurred) LpPLA2 levels in CG (200.1-686.6ng/ml)
users (IDUs) and in comparison group (CG), (p < 0.001,
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ticaria (57.1%), pruritus (55.4%) and itching of the palms
and feet (46.4%). Respiratory obstruction (dyspnea in
42.9%) and arrhythmias (51.8%) were also reported after
heroin use.
In contrast, mild symptoms were documented in 7 of
56 cases (12.5%) after OST within 180 minutes. All of
them showed cutaneous symptoms, including itching of
the palms and feet, pruritus and flushing as well as head-
ache and tiredness.
Discussion
Baseline histamine levels were almost 3-fold higher in
chronic IV opioid abusers than in healthy controls.
Many opiates are known to induce histamine release
by mast cells and basophils causing various effects like
vasodilatation, bronchospasm and pruritus [44,45]. How-
ever, several studies have shown that opioids differ in their
capacity to cause histamine release and vary in opioid-
dependent effects [22,30,46]. Divergent study results can
be explained with the variable dosage of opioids, its mode
and rate of administration, the distribution of histamine
receptors in different tissues, the effects of concomitant
medications and, the heterogeneity of patient responses to
histamine [24,47,48]. Histamine is a non-specific marker
for allergic reactions with a very short half-life [20]. In the
present study it is unlikely that IV heroin is directly re-
sponsible for the observed histamine concentrations. It is
revealing that elevated histamine may be a consequence of
chronic immune activation due to regular heroin use and/
or co-morbidities. In addition to heavy drug use associated
with non-immunological symptoms and side effects, im-
munoglobulin E (IgE) antibody-mediated allergic reactions
to opioids which might be rare have to be considered.
In such cases skin tests with the suspected drug, drug-
specific IgE antibody assays, and flow cytometric activa-
tion of basophils with simultaneous analysis of CD63
appearance may help diagnosis [49].
The immune response is further regulated by the bal-
ance of both histamine and DAO. Reduced DAO levels
were found in IDU (29/56) which might signify low
histamine-degrading capacity, allowing a prolonged pres-
ence of this vasoactive mediator. Therefore, a reason
for elevated histamine in IDU may be competitive in-
hibition of histamine degradation of DAO by other bio-
genic amines, alcohol or drugs. Hence, low DAO levels do
not seem to be specifically associated with anaphylactic
reactions.
Although the mean plasma tryptase levels at baseline
were significantly different in IDU versus the compari-
son group, only 4 of 56 cases tryptase values were above
11.4 μg/l showing marginal elevations (20, 18.8, 17.4 and
17.3 μg/l). A relationship between fatal anaphylaxis and
elevated tryptase levels was shown in previous studies[35,50]. Edston et al. [51] found elevated tryptase levels
in one third of patients who died after heroin intoxica-
tion; however the heroin level was not high enough to
explain the fatalities. Rook et al. [52] reported increased
tryptase concentrations after IV heroin injection in
chronic opioid users, but not after heroin inhalation. This
may be explained by the type of entry itself which may
affect the type of response to the injected substance.
In the present study LpPLA2 concentrations showed
an unexpectedly wide range of variation in both groups.
We observed an up-regulation of LpPLA2 in IDU. It
suggests that increased expression of this enzyme may
be a physiological response to inflammatory stimuli. In
this context, we have to mention that activated basophils
can induce systemic anaphylaxis through the release of
the potent platelet-activating factor (PAF) upon stimula-
tion with immune complexes, even though they present
less than 1% of leukocytes in the body [53,54]. Therefore
LpPLA2 is attributed to play a pivotal role in anaphylaxis
as well as in arteriosclerosis [55].
Our findings clearly indicate that long-term IV heroin
application and oral uptake of Substitol®retard gave rise
to markedly different drug effects. Self-reported allergic
symptoms and side-effects after regular IV heroin appli-
cation were documented in 55 of 56 cases. Most com-
monly cutaneous manifestations (flushing, urticaria,
pruritus) were reported. But in context of the clinical
criteria for diagnosing anaphylaxis, skin symptoms alone
are not indicating an anaphylactic event. Underlying dis-
ease as well as the interference of alcohol or other drugs
taken must be examined to be better understood in this
context. These findings may be explained by the physio-
logical effects of the injected heroin itself. A report by
Haemmig et al. [56], to evaluate the effects of high doses
of injected opiates as prescribed in maintenance of IV
drug users, showed that in 16 of 39 cases, the study has
to be discontinued owing to severe morphine-induced
histamine reactions, such as pruritus, urticaria, nausea
and flushing. Further studies by Grossmann et al. [57]
and Schug et al. [58] described comparable symptoms re-
lated to histamine, like itching around the injection site,
peripheral vasodilatation and asthmatic attacks after the
use of opioids. Though, cases with respiratory involvement
in addition with skin features may indicate a moderately
severe anaphylactic event.
In contrast minimal symptoms, mostly unspecific ones,
were seen after oral substitution medication in 7 of 56
cases. Oral substitution substance was clearly better toler-
ated than IV administered heroin. These results may indi-
cate a well personalized substitution therapy administered
by the medical staff of the withdrawal clinic.
The study is limited by small sample size and lack of
adequate information on the general health condition of
IDU. Obviously, long-term IV opioid dependent persons
Maurer et al. Substance Abuse Treatment, Prevention, and Policy 2014, 9:12 Page 7 of 8
http://www.substanceabusepolicy.com/content/9/1/12suffer poorer health due to the complications of drug
use characterized by cardiovascular diseases, pulmonary
diseases, renal complications, dental problems and gy-
naecological issues in females. Notwithstanding, hepa-
titis B, hepatitis C and human immunodeficiency virus
(HIV) are the predominant infectious diseases in drug ad-
dicts which lead to a weak immune system in this popula-
tion [59,60].
Conclusions
This effort to open the ‘black box’ of anaphylaxis is crit-
ical to our efforts to understand this condition among
IV heroin abusers. This study revealed that baseline his-
tamine concentrations were elevated in chronic IDU, al-
though only relatively small changes in tryptase plasma
levels occurred. After IV heroin application the reported
allergic symptoms were mostly mild and did not lead to
clinically relevant side effects. The substitution sub-
stance was clearly better tolerated than IV administered
heroin. Elevated levels of allergic mediators such as his-
tamine in IDUs may place them at greater risk of severe
or fatal anaphylaxis when exposed to heroin; however,
this requires further investigation.
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